INAVOLISIB, PALBOCICLIB, Faslodex 250 mg solution for injection., INAVOLISIB, PALBOCICLIB, INAVOLISIB, PALBOCICLIB, INAVOLISIB
WO41554
Phase 3 small_molecule active
Quick answer
INAVOLISIB, PALBOCICLIB, Faslodex 250 mg solution for injection., INAVOLISIB, PALBOCICLIB, INAVOLISIB, PALBOCICLIB, INAVOLISIB for HR+/HER2-Negative Locally Advanced or Metastatic Breast cancer with PIK3CA mutation is a Phase 3 program (small_molecule) at Roche Registration Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Roche Registration Limited
- Indication
- HR+/HER2-Negative Locally Advanced or Metastatic Breast cancer with PIK3CA mutation
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active